Pelvic inflammatory disease (PID) guideline (G121)

Warning

Adapted from: UK National Guideline for the Management of Pelvic Inflammatory Disease (2019 Interim update), British Association for Sexual Health and HIV (BASHH)1 

Aetiology

  • PID is an ascending infection from the endocervix which can cause endometritis, salpingitis, parametritis, oophoritis, tubo-ovarian abscess and/or pelvic peritonitis.
  • Can be caused by chlamydia and gonorrhea (25% of cases in the UK), but other organisms such as Gardnerella Vaginalis, Prevotella , Atopobium, Leptotrichia, and Mycoplasma Genitalium have been implicated. 

Image reproduced from RCOG Acute pelvic inflammatory disease (PID): tests and treatment patient information leaflet, November 2016.

Signs and symptoms

Symptoms

  • lower abdominal pain (typically bilateral)
  • deep dyspareunia
  • intermenstrual bleeding, post coital bleeding, menorrhagia
  • purulent vaginal or cervical discharge.

Signs

  • lower abdominal tenderness
  • adnexal tenderness
  • cervical excitation on bimanual examination
  • temp of 38C or above.

Have you considered the differentials?

  • ectopic pregnancy
  • acute appendicitis
  • endometritis
  • ovarian cyst accident
  • urinary tract infection
  • functional pain
  • irritable bowel syndrome (IBS).

 Is there an intrauterine contraceptive device (IUCD) in situ?

Evidence is limited but removal should be considered as may result in better short-term outcomes. Balance this against risk of pregnancy if patient had unprotected sexual intercourse in the previous 7 days. Emergency contraception may be used.

Investigations

  • full blood count /CRP/ liver and renal function tests
  • urine analysis
  • high/low vaginal swab and endocervical swab
  • vulvovaginal nucleic acid amplification test (NAAT) for chlamydia/gonococcus
  • pregnancy test
  • consider pelvic ultrasound (preferably transvaginal)
  • screen for sexually transmitted infections including HIV and syphilis serology
  • CT scan only if tubo-ovarian abscess is suspected or to rule out other causes.

Don't forget! - Contact tracing

  • advise patient to avoid intercourse until they and their partner have completed treatment and follow up
  • screen all sexual contracts within a 6 month period
  • advise condom use
  • offer broad-spectrum antibiotic to male partners
  • refer to NES Antimicrobial Companion

Treatment

Analgesia and antibiotics.

Outpatient

Inpatient

Consider if:

  1. surgical emergency cannot be excluded
  2. lack of response to oral therapy
  3. clinically severe disease (e.g. pyrexia =/> to 38 C)
  4. presence of tubo-ovarian abscess
  5. intolerance to oral therapy
  6. pregnancy

Refer to NES Antimicrobial Companion

Other things to consider: pregnancy

  • It is associated with an increase in both maternal and fetal morbidity, therefore parenteral therapy is advised.
  • Note: discuss safety profile of drugs with patient.

What about surgical management?

  • Laparoscopy may help by dividing adhesions or draining pelvic abscesses. This may improve antibiotic penetration to infective tissues.
  • One may also consider ultrasound-guided drainage of pelvic fluid collections.
  • Adhesiolysis in peri-hepatitis is possible – but there is no evidence if this is superior to only antibiotic therapy.

Follow-up

  • If no improvement in signs and symptoms within 48 hours:

Consider further investigations, intravenous therapy (if already on iv, discuss with microbiology if change in antibiotics regimen required) and/or surgical management.

  • Do a further review under named gynaecology consultant, if attended gynaecology acute admission. This is to:
    • assess response to treatment
    • check compliance
    • ensure partner notification has been undertaken, and take/arrange further syphilis and HIV tests if presentation was during the window periods
    • ensure patients aware of PID sequelae like chronic pain, infertility, ectopic pregnancy
    • to do a pregnancy test if required
    • repeat tests for chlamydia and gonorrhea if baseline tests were negative and symptoms persist
    • discuss, if necessary, to refer on to sexual health.

Editorial Information

Last reviewed: 20/10/2022

Next review date: 20/10/2025

Author(s): Acharya S.

Version: 02.1

Author email(s): santanu.acharya2@aa.nhs.scot, susan.cross@aa.nhs.scot.

Co-Author(s): Mufti N, Cross S.

Approved By: Gynaecology CG Group

References

1. British Association for Sexual Health and HIV. United Kingdom National Guideline for the Management of Pelvic Inflammatory Disease (2019 Interim Update). https://www.bashh.org/_userfiles/pages/files/resources/pidupdate2019.pdf 

2. NICE CKS. Pelvic inflammatory disease. https://cks.nice.org.uk/topics/pelvic-inflammatory-disease/ [Accessed 23/11/2022]